Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease

Keyphrases

• Biochemical Effects 100%
• Chronic Liver Disease 100%
• Pharmacokinetic Effects 100%
• Ammonia 66%
• Albumin 66%
• Cholesterol Levels 66%
• Escalating Dose 66%
• Partial Thromboplastin Time 66%
• Cellular Level 33%
• Human Studies 33%
• Liver Disease 33%
• Pharmacokinetics 33%
• Multiple Dose 33%
• Clinical Utility 33%
• Potential Gains 33%
• High Density 33%
• Dosing Regimen 33%
• Hemoglobin 33%
• Bilirubin 33%
• Hepatocyte Proliferation 33%
• Red Blood Cells 33%
• Downward Trend 33%
• Dose Level 33%
• Low-density Lipoprotein Cholesterol (LDL-C) 33%
• Hepatocyte Growth Factor 33%
• Child-Pugh Score 33%
• Liver Function Tests 33%
• Total Bilirubin 33%
• Hepatic Encephalopathy 33%
• Non-viral Liver Diseases 33%

Biochemistry, Genetics and Molecular Biology

• Pharmacokinetics 100%
• Cholesterol Level 100%
• Partial Thromboplastin Time 100%
• Bilirubin 100%
• Cytokine 50%
• Animal Experiment 50%
• Hepatocyte 50%
• Hepatocyte Growth Factor 50%
• Hemocyte 50%
• Human Study 50%
• Hepatitis Virus 50%
• Liver Function Test 50%
• Low-Density Lipoprotein 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Liver Disease 100%
• Pharmacokinetics 100%
• Bilirubin 66%
• Thromboplastin 66%
• Human Study 33%
• Cytokine 33%
• Liver Disease 33%
• Low Density Lipoprotein Cholesterol 33%
• Scatter Factor 33%
• Virus Hepatitis 33%
• Hepatic Encephalopathy 33%